Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 7/20 | 0.43 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.43 |
| ▸ | F11 | P03951 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.38 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | CCNC | P24863 | 2/20 | 0.37 |
| ▸ | CDK8 | P49336 | 2/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | DGKZ | Q13574 | 1/20 | 0.34 |
| ▸ | IDH1 | O75874 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23242933 | 0.82 | PDE1B (0.34) | LPLLIPGTLR7PDE1BPDE10A | |
| SCHEMBL23262957 | 0.82 | PDE1B (0.34) | LPLLIPGTLR7PDE1BPDE10A | |
| SCHEMBL15324898 | 0.78 | TLR7 (0.43) | TLR7PDE1BJAK2JAK1CCNC | |
| SCHEMBL22425610 | 0.78 | TLR7 (0.43) | TLR7PDE1BJAK2JAK1CCNC | |
| SCHEMBL24104471 | 0.78 | LPL (0.47) | LPLLIPGF11ESR2 | |
| SCHEMBL1929059 | 0.76 | JAK2 (0.43) | TLR7PDE1BJAK2JAK1CCNC | |
| SCHEMBL15317724 | 0.75 | TLR7 (0.41) | TLR7PDE1BJAK2JAK1CCNC | |
| SCHEMBL9953021 | 0.73 | KCNJ1 (0.45) | PDE1BJAK2JAK1 | |
| SCHEMBL24104472 | 0.72 | LPL (0.46) | LPLLIPGF11ESR2 | |
| SCHEMBL30613529 | 0.71 | ALDH1A1 (0.54) | LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240425499-A1 | TYRO3 INHIBITORS | HALIA THERAPEUTICS INC (US) | 2024-12-26 | — | — | US | disclosed |
| WO-2023064218-A1 | TYRO3 INHIBITORS | Halia Therapeutics, Inc. (US) | 2023-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240425499-A1 | TYRO3 INHIBITORS | TYRO3, TYR, TH | LPL 2136/4885LIPG 1349/4885F11 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.